| Title: |
Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial. |
| Authors: |
UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales; UCL - (MGD) Service de rhumatologie; Bertrand, Delphine; Joly, Johan; Neerinckx, Barbara; Durez, Patrick; Lenaerts, Jan; Joos, Rik; Thevissen, Kristof; Zwaenepoel, Tom; Vanhoof, Johan; Di Romana, Silvana; Taelman, Veerle; Van Essche, Els; Corluy, Luk; Ribbens, Clio; Vanden Berghe, Marc; Devinck, Mieke; Ajeganova, Sofia; Durnez, Anne; Boutsen, Yves; Margaux, Joëlle; Peene, Isabelle; Van Offel, Jan; Doumen, Michaël; Pazmino, Sofia; De Meyst, Elias; Kulyk, Myroslava; Creten, Nelly; Westhovens, René; Verschueren, Patrick; CareRA2020 Study group; Blondiaux, Gilles; Brasseur, Jean-Pierre; Montigny, Pauline; Dierckx, Stéphanie |
| Source: |
RMD open, Vol. 10, no.3 (2024) |
| Publisher Information: |
2024 |
| Document Type: |
Electronic Resource |
| Abstract: |
To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second remission-induction attempt. CareRA2020 (NCT03649061) was a 2-year, open-label, multicentre, pragmatic randomised controlled trial. Treatment-naïve patients started MTX and GC bridging (COBRA-Slim: CS). Within a time window from week (W) 8 until W32, early insufficient responders (28-joint Disease Activity Score - C-reactive Protein (DAS28-CRP) >3.2 between W8 and W32 or ≥2.6 at W32) were randomised to a Standard-CS strategy (adding leflunomide first) or Bio-induction-CS strategy (adding etanercept for 24 weeks). Additional treatment adaptations followed the treat-to-target principle. Longitudinal disease activity (DAS28-CRP) over 104 weeks (primary outcome), achievement of DAS28-CRP |
| Index Terms: |
Humans; Etanercept; Methotrexate; Arthritis, Rheumatoid; Male; Female; Middle Aged; Antirheumatic Agents; Glucocorticoids; Treatment Outcome; Drug Therapy, Combination; Aged; Adult; Remission Induction; Severity of Illness Index; biological therapy; early rheumatoid arthritis; glucocorticoids; methotrexate; info:eu-repo/semantics/article |
| URL: |
http://hdl.handle.net/2078.1/290641 |
| Availability: |
Open access content. Open access content; info:eu-repo/semantics/openAccess |
| Note: |
English |
| Other Numbers: |
UCDLC oai:dial.uclouvain.be:boreal:290641; boreal:290641; info:doi/10.1136/rmdopen-2024-004535; info:pmid/39117445; urn:EISSN:2056-5933; 1508047405 |
| Contributing Source: |
UNIVERSITE CATHOLIQUE DE LOUVAIN; From OAIster®, provided by the OCLC Cooperative. |
| Accession Number: |
edsoai.on1508047405 |
| Database: |
OAIster |